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Abstract
Aberrant activation of the nucleotide-binding domain and leucine-rich repeat related (NLR) family, pyrin
domain containing 3 (NLRP3) inflammasome drives the development of many complex inflammatory diseases,
such as obesity, Alzheimer’s disease, and atherosclerosis. However, no medications specifically targeting the
NLRP3 inflammasome have become clinically available. Therefore, we aim to identify new inhibitors of the
NLRP3 inflammasome in this study.
Methods: Vesicle-like nanoparticles (VLNs) were extracted from garlic chives and other Allium vegetables and
their effects on the NLRP3 inflammasome were evaluated in primary macrophages. After garlic chive-derived
VLNs (GC-VLNs) were found to exhibit potent anti-NLRP3 inflammasome activity in cell culture, such function
was further assessed in a murine acute liver injury disease model, as well as in diet-induced obesity. Finally,
GC-VLNs were subjected to omics analysis to identify the active components with anti-NLRP3 inflammasome
function.
Results: GC-VLNs are membrane-enclosed nanoparticles containing lipids, proteins, and RNAs. They
dose-dependently inhibit pathways downstream of NLRP3 inflammasome activation, including caspase-1
autocleavage, cytokine release, and pyroptotic cell death in primary macrophages. The inhibitory effects of
GC-VLNs on the NLRP3 inflammasome are specific, considering their marginal impact on activation of other
inflammasomes. Local administration of GC-VLNs in mice alleviates NLRP3 inflammasomemediated inflammation in chemical-induced acute liver injury. When administered orally or intravenously,
GC-VLNs accumulate in specific tissues and suppress activation of the NLRP3 inflammasome and chronic
inflammation in diet-induced obese mice. The phospholipid 1,2-dilinoleoyl-sn-glycero-3-phosphocholine
(DLPC) in GC-VLNs has been identified to inhibit NLRP3 inflammasome activation.
Conclusions: Identification of GC-VLNs and their active component DLPC as potent inflammasome
inhibitors provides new therapeutic candidates in the treatment of NLRP3 inflammasome-driven diseases.
Key words: Nanoparticles, vesicles, garlic chive, NLRP3 inflammasome, obesity

Introduction
The NLRP3 inflammasome protein complex is
formed by NLRP3, apoptotic speck protein containing
a caspase recruitment domain (ASC) and caspase-1
(Casp1) [1,2]. As a vital player in the innate immune

system, NLRP3 inflammasome’s activation is tightly
regulated through a two-step process − it must first be
primed and then be assembled [3,4]. Priming signals,
such as lipopolysaccharide (LPS) or tumor necrosis
http://www.thno.org
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factor alpha (TNFα), upregulate transcription of the
Nlrp3 and Il1b genes through activation of nuclear
factor-κB (NF-κB) signaling and induce posttranslational modifications of NLRP3 protein. A
variety of stimuli from pathogens, hosts, or the
environment,
such
as
nigericin,
adenosine
triphosphate (ATP), alum, serve as activating signals
to trigger the assembly and activation of the NLRP3
inflammasome, leading to autocleavage of Casp1.
Casp1 cleaves itself to generate Casp1 p10 and p20,
which in turn cleave 1) gasdermin D to induce
pyroptotic cell death and 2) pro-interleukin (IL)-1β
and pro-IL-18 to release mature cytokines IL-1β and
IL-18. Genetic evidence indicates that both cytokine
release and pyroptosis are essential contributors to the
NLRP3
inflammasome-mediated
inflammatory
process [5]. Inappropriate activation of the NLRP3
inflammasome has been implicated in many diseases,
such
as
obesity
[6],
cryopyrin-associated
autoinflammatory syndrome [7], Alzheimer’s disease
[8], atherosclerosis [9], and gout [10]. Therefore, the
NLRP3 inflammasome has been considered to be a
highly desirable drug target, but therapeutics
specifically targeting this protein complex has not
become available in clinical practice.
In obesity, the increased levels of circulating LPS
from gut microbiota [11,12] and accumulated
metabolic stress molecules (such as free fatty acids
[FFAs] and cholesterol crystals) [2-4] act as the
priming and activating signals, respectively, and lead
to assembly and activation of the NLRP3
inflammasome. Reduced expression of the NLRP3
gene in adipose tissue is correlated with decreased
inflammation and improved insulin sensitivity in
obese type 2 diabetic patients [6]. Genetic deletion of
the Nlrp3, Pycard (Asc), or Casp1 genes has been shown
to improve glucose homeostasis, accompanied by
decreased inflammatory cytokines in the serum and
reduced expression of inflammatory genes in adipose
tissues in diet-induced obese mice [6,13,14].
Fulminant hepatic failure is a rare acute hepatic
disorder associated with high mortality [15].
Administering D-galactosamine (GalN) and LPS in
mice induces acute inflammation and liver injury,
simulating many clinical features of fulminant hepatic
failure [16]. The chemical inhibitor of the NLRP3
inflammasome, MCC950, alleviates inflammation and
liver damage in GalN/LPS-challenged mice [17],
suggesting critical involvement of the NLRP3
inflammasome in this disease model.
Dietary vesicle-like nanoparticles (VLNs) have
been recently identified in many commonly
consumed foods, including bovine milk, broccoli,
ginger, apple, and honey [18-22]. These dietary VLNs
are membrane-enclosed nanoparticles (50-300 nm in
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diameter) containing proteins, lipids, and RNAs.
Growing evidence indicates that dietary VLNs are
stable, bioavailable, and bioactive in consumers. The
membrane of a dietary VLN encloses the
biomolecules inside the nanoparticle, thus conferring
stability and resistance to solutions in the stomach
and intestines and protecting the biomolecules from
degradation [23]. As a result, dietary VLNs are able to
reach target tissues where they exert their bioactivity.
For example, it has been found that orally
administered ginger VLNs accumulate in the liver,
induce expression in the liver of detoxifying/
antioxidant genes, including Hmox1, Nqo1, Gclm, and
Gclc, and ameliorate liver damage caused by alcohol
consumption in mice [24]. Grape-derived VLNs are
taken up by intestinal stem cells and promote their
proliferation through regulation of the Wnt/β-catenin
signaling pathway [25]. The bioavailability, stability,
and bioactivity of these dietary VLNs confer upon
them high therapeutic potential. Therefore, we sought
to screen dietary VLNs for anti-NLRP3 inflammasome
activities.

Results
Characterization of VLNs from garlic chives
Many species in the genus Allium, such as garlic,
leek, onion, and scallion, are commonly consumed
throughout the world. Many of them have
anti-inflammatory properties [26]. Therefore, in this
study, we selected six vegetables from the Allium
genus for VLN extraction and assessed the effects of
their VLNs on the NLRP3 inflammasome. Bulbs of
garlic (A. sativum) and purple or white onion (A. cepa)
and leaves of leek (A. ampeloprasum), scallion (A.
fistulosum), and garlic chive (A. tuberosum) were
minced and subjected to VLN extraction using the
protocol established in our laboratory [19,27]. VLNs
were obtained from all Allium vegetables.
Nanoparticle tracking analysis (NTA) showed that
sizes of Allium-derived VLNs ranged from 113 nm to
153 nm in diameter (Figure S1A). The yields of
Allium-derived VLNs varied from 1.5×1011 g-1 to
8.9×1011 g-1 (Figure S1B). To evaluate the effects of
Allium-derived VLNs on NLRP3 inflammasome
activity, these nanoparticles were incubated with
murine
bone
marrow-derived
macrophages
(BMDMs), followed by NLRP3 inflammasome
activation using LPS and ATP. Antibodies against
macrophage surface markers F4/80 [28] and CD11b
[29] were used to validate the macrophage identity of
BMDMs. Over 96% of BMDMs were F4/80 and
CD11b double positive (Figure S1C), suggesting that
the majority of BMDMs were indeed macrophages.
Most Allium-derived VLNs had marginal or mild
http://www.thno.org
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inhibitory effects on the level of the Casp1
autocleavage product Casp1 p10 in cell lysates upon
activation of the NLRP3 inflammasome, but GCVLNs strongly inhibited Casp1 autocleavage (Figure
S1D). Therefore, GC-VLNs were chosen for further
studies.
The vesicle-like features of GC-VLNs were
assessed in detail. Scanning electron microscopy
(SEM) showed that GC-VLNs were well-dispersed
individual ball-like nanoparticles (Figure 1A), and
ultrastructure transmission electron microscopy
(TEM) demonstrated that GC-VLNs were enclosed by
a membrane structure (Figure 1B). Detergent
treatment is a simple way to distinguish between
protein aggregates and membrane-enclosed particles,
because protein aggregates are much more resistant to
detergent-based lysis than membrane-bound particles
[30]. The non-ionic detergent Triton X-100, which
disrupts lipid-lipid interaction and lipid-protein
interaction [30], was found to lyse GC-VLNs and
therefore
reduce
GC-VLN
numbers
in
a
dose-dependent manner (Figure 1C), further
confirming the membrane-bound nature of GC-VLNs.
Biomolecule
analysis
revealed
that
these
nanoparticles contained small-sized RNAs, proteins,
and lipids (Figure 1D-F).
The proteins in GC-VLNs were subjected to
proteomics analysis using the reference proteome
database viridiplantae, because the proteome of garlic
chive was unavailable. A variety of proteins were
identified in GC-VLNs (Table S1). A series of plasma
membrane proteins, such as plasma membrane
ATPase, ABC transporter G family member,
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pleiotropic
drug
resistance
protein,
and
hypersensitive-induced response protein, were found
in GC-VLNs. Clathrin heavy chain and light chain
and Ras-related protein, cytosolic proteins that are
known to associate with plasma membrane [31,32],
were identified in GC-VLNs. The presence of plasma
membrane proteins and cytosolic proteins that
interacted with the plasma membrane in GC-VLNs
supported their vesicle-like properties.

GC-VLNs suppressed NLRP3 inflammasome
activation
In obesity, increased levels of LPS and FFA often
serve as priming and activating signals, respectively,
to activate the NLRP3 inflammasome [33]. Therefore,
to mimic obesity condition in vitro, we first pre-treated
BMDMs with GC-VLNs, followed by LPS priming
and FFA treatment to activate the NLRP3
inflammasome. Remarkably, GC-VLNs suppressed all
the downstream events of NLRP3 inflammasome
activation in a dose-dependent manner, including
Casp1 autocleavage (Figure 2A), IL-1β secretion
(Figure 2B), IL-18 secretion (Figure 2C), and
pyroptosis (Figure 2D). We were not able to detect the
Casp1 autocleavage product Casp1 p10 and its
cleaved mature IL-1β in the culture media using
immunoblot analysis, possibly because of relative
weak activation of the NLRP3 inflammasome by FFA.
The levels of Casp1 p10 in cell lysates are generally
consistent with its levels in culture media [34-36].
Therefore we conducted immunoblot analysis of
Casp1 p10 using cell lysates to monitor the Casp1
autocleavage status. Activation of NF-κB signaling via

Figure 1. Characterization of GC-VLNs. (A) Representative SEM images of GC-VLNs. (B) Ultrastructure TEM images of GC-VLNs. (C) Effects of Triton X-100 treatment
on nanoparticle numbers of GC-VLNs. Triton X-100 (TX) at different concentrations was used to lyse GC-VLNs, followed by measurement of particle numbers. Results were
expressed as mean±SEM from three independent experiments. * (p < 0.05) and ** (p < 0.01) compared with the sample without Triton X-100 treatment (black bar). (D) Agarose
gel of RNAs extracted from GC-VLNs. 2.5% agarose gel was used. RNA ladder: 50-1000 nucleotides (nt). (E) Coomassie blue staining of protein gel of GC-VLN proteins. 4-12%
NuPAGE Bis-Tris protein gel was used. Protein ladder: 10-250 kDa. (F) CuSO4/phosphoric acid staining of GC-VLN lipids on a thin layer chromatography (TLC) silica gel plate.
10% CuSO4 in 8% phosphoric acid was used to visualize the lipid bands.

http://www.thno.org
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LPS priming leads to release of two potent cytokines
IL-6 and TNFα [37]. Interestingly, GC-VLNs also
suppressed the release of both IL-6 and TNFα (Figure
S2A-B). In peritoneal macrophages, GC-VLNs also
suppressed Casp1 autocleavage when the NLRP3
inflammasome was activated using LPS and FFA
(Figure 2E). The inhibitory effects of GC-VLNs on the
NLRP3 inflammasome were specific because
GC-VLNs did not inhibit Casp1 autocleavage
mediated by the Absent in Melanoma 2 (AIM2)
inflammasome (Figure 2F). AIM2 senses cytosolic
DNAs during bacterial or viral invasion, recruits ASC
and Casp1 to form the AIM2 inflammasome, and
leads to Casp1 autocleavage and activation [1,2].
ATP is a commonly used stimulus to activate the
NLRP3 inflammasome [38]. When the NLRP3
inflammasome was activated by ATP in LPS-primed
BMDMs, GC-VLNs dose-dependently decreased the
level of Casp1 p10 in the cell lysates and culture
media (Figure 2G). IL-1β release was also decreased
by GC-VLN treatment, as indicated by IL-1β
immunoblot analysis of the media (Figure 2G) and
IL-1β ELISA analysis (Figure S3A). Secretion of IL-18
and pyroptotic cell death were consistently alleviated
by GC-VLNs (Figure S3B-C). GC-VLNs also blunted
Casp1 autocleavage when the NLRP3 inflammasome
was activated by ATP in LPS-primed peritoneal
macrophages (Figure S3D). A time-course experiment
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demonstrated that incubation for at least 6 h was
needed
for
GC-VLNs
to
inhibit
NLRP3
inflammasome-mediated Casp1 autocleavage (Figure
S3E). In addition, GC-VLNs inhibited NLRP3
inflammasome-mediated Casp1 autocleavage when it
was activated by other stimuli, such as nigericin or
alum (Figure 2H).
The cellular events targeted by GC-VLNs during
NLRP3 inflammasome activation were further
investigated. GC-VLNs had marginal effects on the
levels of either inflammasome subunits (NLRP3,
Casp1, and ASC), pro-IL-1β, or the critical
inflammasome modulator never in mitosis gene a
(NIMA)-related kinase 7 (Nek7) [35] (Figure S4A).
When the sensor NLRP3 is activated, it forms
oligomers, recruits the adaptor ASC, and induces ASC
oligomerization. The oligomerized ASC further
recruits the effector Casp1 to form an oligomerized
protein complex with high molecular mass [39]. The
ASC oligomerization assay showed that GC-VLNs
suppressed ASC oligomerization (Figure S4B). The
NLRP3 inflammasome complex with high molecular
mass can be detected as a single speck in each
macrophage cell using ASC immunofluorescence
staining [35]. GC-VLN treatment reduced the speck
formation in BMDMs (Figure S4C-D). Therefore,
GC-VLNs seemed to impede assembly and formation
of the NLRP3 inflammasome complex.

Figure 2. GC-VLNs specifically inhibited NLRP3 inflammasome activation. (A-D) BMDMs were preincubated with GC-VLNs for 16 h, primed with LPS for 3 h, and
stimulated with FFA sodium palmitate for 12 h to activate the NLRP3 inflammasome. Cells were lysed for immunoblot analysis of Casp1 p10 (A), and the cell-free media were
subjected to enzyme-linked immunosorbent assay (ELISA) analysis to measure the release of IL-1β (B) and IL-18 (C). Pyroptotic cell death was assessed by measuring the level
of lactate dehydrogenase (LDH) released in the culture media (D). (E) Immunoblot analysis of Casp1 p10 in lysates of peritoneal macrophages preincubated with GC-VLNs for
16 h, followed by NLRP3 inflammasome activation using LPS and FFA. (F) Immunoblot analysis of Casp1 p10 in cell lysates of BMDMs preincubated with GC-VLNs for 16 h,
followed by AIM2 inflammasome activation. (G) Immunoblot analysis of Casp1 and IL-1β in cell lysates and culture media of BMDMs preincubated with GC-VLNs for 16 h, primed
with LPS for 3 h, and stimulated with ATP for 30 min to activate the NLRP3 inflammasome. (H) Immunoblot analysis of Casp1 p10 in lysates of LPS-primed BMDMs, in which the
NLRP3 inflammasome was activated by nigericin (Ni) or alum. 9×1010 mL-1 of GC-VLNs were used to pretreat the cells for 16 h. Results were expressed as mean±SEM from three
independent experiments. * (p < 0.05) and ** (p < 0.01) compared with LPS+FFA group (black bar). Tubulin was included to show equivalent loading in immunoblot analysis.
LPS-treated macrophages were used as a negative control for inflammasome activation.

http://www.thno.org
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Figure 3. GC-VLNs alleviated inflammation in chemical-induced acute liver injury in mice. 8-week-old male C57BL/6J mice were intraperitoneally injected with the
solvent phosphate-buffered saline (PBS) or GC-VLNs in PBS at 1×1010 g-1. 48 h later, acute liver injury was induced by intraperitoneal injection of GalN/LPS mixture. The mice
were sacrificed 6 h after GalN/LPS injection. N = 4/group. (A) Representative images of liver sections with hematoxylin and eosin (H&E) staining. (B) Levels of AST and ALT in
serum. (C) Levels of IL-1β in serum. (D) Levels of IL-18 in serum. (E) Relative mRNA levels of Nlrp3, Pycard, Casp1, and Il1b genes in the livers. The housekeeping gene
hypoxanthine guanine phosphoribosyl transferase (Hprt) was used to normalize mRNA levels. (F) Immunoblot analysis of liver lysates. Data were presented as mean±SEM. * (p
< 0.05) and ** (p < 0.01) compared with the control group (bar with white squares).

GC-VLNs were labeled with a lipophilic dye
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine
perchlorate (DiI) and incubated with BMDMs.
GC-VLNs were taken up by BMDMs in a
dose-dependent manner (Figure S5A). In the
time-course experiment, DiI-labeled GC-VLNs were
detected in BMDMs after 3 h incubation and
accumulated in cells over the time (Figure S5B).
Proteins inside GC-VLNs were labeled with Exoglow
protein dye, and these protein-labeled GC-VLNs
accumulated dose-dependently in BMDMs (Figure
S5C). When RNAs in GC-VLNs were labeled with
Exoglow RNA dye, they were also readily detected in
primary macrophages (Figure S5D). Together, these
uptake experiments suggested that intact GC-VLNs
and their contents (proteins and RNAs) were taken up
by BMDMs.

GC-VLNs reduced inflammation during acute
liver injury
Administration of GalN and LPS through
intraperitoneal injection triggers acute liver injury and
inflammation in mice [16]. MCC950, a specific
chemical inhibitor of the NLRP3 inflammasome,
suppresses inflammation and liver damage in this
disease model [17]. We confirmed the critical
involvement of the NLRP3 inflammasome in this
disease model using a mouse strain without
expression of the NLRP3 protein (Figure S6A). A

mixture of GalN and LPS was injected in Nlrp3-/- mice
and their wildtype (wt) littermates to induce acute
liver injury. The mice were sacrificed after 6 h. The
level of serum IL-1β in the Nlrp3-/- mice was much
lower compared to their wt littermates after
GalN/LPS challenge (Figure S6B), suggesting that
acute inflammation in this disease model was largely
dependent on the NLRP3 inflammasome. Therefore,
this disease model was used to assess the anti-NLRP3
inflammasome function of GC-VLNs in vivo in our
initial proof-of-concept study.
GC-VLNs were intraperitoneally injected into
C57BL/6J mice. The therapeutic agent delivered
through intraperitoneal injection would be primarily
absorbed into the mesenteric vessels, drain directly
into the portal vein, and pass through the liver [40].
Therefore, this local injection route was chosen to
efficiently deliver GC-VLNs to the liver. Considering
the absorption process of GC-VLNs, the minimum 6 h
of treatment needed to observe the antiinflammasome function of GC-VLNs in vitro, as well
as our preliminary time-course in vivo test, we
decided to wait for 48 h after GC-VLN administration
to inject a mixture of GalN and LPS into mice to
induce acute liver injury. GC-VLNs remarkably
alleviated severe liver bleeding and cellular damage
to hepatocytes caused by the GalN/LPS challenge
(Figure 3A). The levels of alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) in
http://www.thno.org
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circulation are often used as indicators of liver injury
[41]. GC-VLNs significantly lowered the circulation
levels of ALT and AST induced by GalN/LPS (Figure
3B). The levels of circulating IL-1β and IL-18, two
downstream cytokines of NLRP3 inflammasome
activation, were suppressed by GC-VLNs (Figure
3C-D). In the livers, GC-VLNs reduced both mRNA
and protein levels of the Nlrp3, Casp1, and Il1b genes
(Figure 3E-F). GC-VLNs had no impact on the protein
levels of NLRP3, Casp1, and pro-IL-1β in BMDMs
(Figure S4A). The exact reasons for the differential
effects of GC-VLNs in vitro and in vivo were not clear.
It has been reported that mature IL-1β is responsible
for recruiting macrophages [42]. Therefore, it is
plausible that GC-VLNs suppressed the NLRP3
inflammasome and thus led to diminished mature
IL-1β, which in turn reduced macrophage infiltration
and detection of inflammatory gene expression in
liver tissue. Considering the inhibitory effects of
GC-VLNs on IL-6 and TNFα in vitro, the levels of
these cytokines in serum during acute liver injury
were measured. Surprisingly, the levels of IL-6 and
TNFα in circulation were not significantly affected by
GC-VLNs (Figure S6C), but the transcription of Il6
and Tnf genes was decreased by GC-VLN treatment
(Figure S6D). Together, GC-VLNs reduced acute
inflammatory responses and alleviated liver injury in
GalN/LPS-challenged mice. The potent antiinflammatory activities of GC-VLNs in acute liver
inflammation prompted us to further investigate their
therapeutic potential in chronic inflammation in
obesity.

GC-VLNs were distributed in specific tissues in
mice
The bioavailability of GC-VLNs in vivo was
evaluated using fluorescence-labeled GC-VLNs. An
ExoGlow-Vivo EV labeling kit was used to covalently
link fluorescence dye to proteins on the membranes of
GC-VLNs, which excluded the possibility of dye
dissociation often reported for the lipophilic
fluorescence dyes [24]. Systemic delivery of
therapeutic agents is often achieved through
parenteral (outside the digestive tract) and enteral
(through digestive tract) administration [40].
Intravenous injection is a typical parenteral
administration that leads to higher bioavailability,
compared to enteral approaches, because it bypasses
absorptive processes and hepatic metabolism of the
agent. However, enteral approaches (typically oral
administration) are less invasive and patient friendly.
Therefore, we chose both intravenous and oral
administration to assess the biodistribution of
GC-VLNs. When GC-VLNs with fluorescence
intensity (FI) of 3,500 g-1 were injected intravenously
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in lean healthy mice, the fluorescence signals of the
GC-VLNs were detected in the liver, spleen, kidney,
lung, brown adipose tissue (BAT), epididymal white
adipose tissue (eWAT), and heart; however,
intravenous injection of a free dye control with the
same 3,500 FI g-1 led to no fluorescence signals in any
of the examined tissues (Figure S7A-C). When 3,500 FI
g-1 of GC-VLNs were given intravenously to
diet-induced obese C57BL/6J mice, the labeled
GC-VLNs accumulated in liver, spleen, kidney, lung,
eWAT, heart, bone, and gastrointestinal (GI) tract
(Figure 4A-B). It is interesting to note that the
distribution patterns of GC-VLNs in lean and obese
mice largely overlapped, with only a slight difference.
For oral administration, we found that 60,000 FI
g-1 (approximately 0.6×1010 nanoparticles g-1) of
GC-VLNs were needed to detect fluorescence signals
in the GI tract and kidney in lean mice (Figure S8A-C).
Oral administration of free dye with the same
fluorescence intensity led to detection of fluorescence
signals in the GI tract. We reasoned that possible free
dye contamination in 60,000 FI g-1 of GC-VLNs should
be much lower than 60,000 FI g-1. In our labeling
procedure, GC-VLNs were washed with PBS twice
after labeling. The fluorescence intensity of free dye
from the first wash was approximately 3,600/0.6×1010
nanoparticles and the fluorescence intensity of free
dye from the second wash was around 1,200/0.6×1010
nanoparticles. Therefore, we decided to use free dye
control at 7,000 FI g-1, which should be much higher
than any possible contamination from free dye in the
final labeled GC-VLNs. Oral administration of this
free dye control did not lead to detection of significant
fluorescence signal in any tissues (Figure S8A-C).
When 60,000 FI g-1 of GC-VLNs were orally
administered to diet-induced obese C57BL/6J mice,
GC-VLNs were found in the GI tract, kidney, and
eWAT (Figure 4A and C). The distribution patterns of
orally administered GC-VLNs in lean and obese mice
were also similar, but GC-VLNs accumulated
significantly in eWAT in obese mice.

GC-VLNs improved metabolic health and
reduced inflammation in obesity
To assess the effects of GC-VLNs on NLRP3
inflammasome-mediated chronic inflammation in
obesity, we fed C57BL/6J mice with a high-fat diet
(HFD) for 15 weeks to induce obesity and
obesity-associated chronic inflammation. When the
HFD feeding was started, the mice were randomly
separated into three groups: mice in the control group
received PBS weekly; mice in VLN-IV group were
administered with GC-VLNs weekly through
intravenous injection (IV); and mice in VLN-OG
group were given GC-VLNs weekly through oral
http://www.thno.org
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gavage (OG). GC-VLNs had no significant effects on
the body weight of mice during the entire experiment
(Figure 5A). After 11 weeks of treatment, the mice
were subjected to metabolic cage analysis. OG- or
IV-administered GC-VLNs had marginal impact on
food intake, water intake, and general activity (Figure
5B), indicating that GC-VLNs did not cause any
detrimental side effects in mice after 11 weeks of
administration. After 13 weeks, mice were subjected
to a glucose tolerance test. The mice treated with
either IV- or OG-administered GC-VLNs cleared
blood glucose more efficiently compared to the
control group (Figure 5C-D), indicating improved
glucose homeostasis in GC-VLN-treated mice. Upon
sacrifice, the level of IL-6 in serum was found to be
significantly lower in the VLN-IV group, and the level
of serum IL-18 tended to be lower in both VLN-IV and
VLG-OG mice, compared to the control mice, but the
difference did not reach statistical significance (Figure
5E). Levels of IL-1β and TNFα in the serum were
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undetectable in all the mice.
Obesity-associated inflammation and NLRP3
inflammasome activation initially arise in WAT
[43,44]. Therefore, we mainly focused on the eWAT of
these mice. Interestingly, the percentage of eWAT in
the VLN-IV group was similar to that in the control
group, but the percentage of eWAT in the VLN-OG
group was higher than in the control group (Figure
6A). In hematoxylin and eosin (H&E)-stained eWAT
slides, crown-like structures (CLSs) were observed in
the eWAT in diet-induced obese mice (Figure 6B, left
panel). The CLSs, in which macrophages accumulate
around dying or dead adipocytes, are a histologic
hallmark indicating the proinflammatory state of
eWAT [45,46]. GC-VLN treatment, especially in the
VLN-OG mice, reduced the numbers of CLSs (Figure
6B, middle and right panels). The stromal vascular
fraction (SVF) of eWAT, which contains immune cells
such as adipose tissue macrophages, adipose-derived
stem cells, fibroblasts, and endothelial cells [47,48],

Figure 4. Distribution of GC-VLNs covalently linked to a fluorescence dye in diet-induced obese mice. GC-VLNs were covalently labeled with a fluorescence dye
in near infrared ranges. The labeled GC-VLNs were intravenously administered at 3,500 FI g-1 or orally given at 60,000 FI g-1 to male C57BL/6J mice, which were fed with a HFD
for 15 weeks. 6 h later, the mice were sacrificed to collect tissues to measure the fluorescence signals in each type of tissue. N = 3/group. (A) Representative images of mouse
tissues under Licor Odyssey Clx image system. (B) Fluorescence signal intensity of mouse tissues collected from control mice received with the solvent PBS and mice
intravenously injected with GC-VLNs in PBS (VLN-IV). (C) Fluorescence signals of mouse tissues collected from control mice and mice orally administered with GC-VLNs
(VLN-OG). Data were presented as mean±SEM. * (p < 0.05) and ** (p < 0.01) compared with the control PBS group (bar with white squares).
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was extracted, stained with antibodies against F4/80
(surface marker of macrophages) [28], and subjected
to flow cytometry analysis. Orally administered
GC-VLNs
remarkably
reduced
macrophage

9318
infiltration (Figure 6C-D). Both flow cytometry and
histological analysis suggested that GC-VLNs
reduced immune cell infiltration in eWAT in
diet-induced obese mice.

Figure 5. GC-VLNs improved metabolic health in diet-induced obese mice. 8-week-old male C57BL/6J mice were fed with a HFD, and GC-VLNs were given through
oral gavage (VLN-OG) or intravenous injection (VLN-IV) at the dose of 1×1010 g-1 weekly when the HFD feeding started. N = 7-8 for each condition. (A) Body weight gain of the
mice between 8 and 22 weeks of age. (B) Food intake, water intake, and movement counts. After 11-week treatment, the mice were individually kept in metabolic cages for 48
h. The data from the final 24 h were used for the calculation. (C) Intraperitoneal glucose tolerance test (ipGTT). After 13-week treatment, the mice were intraperitoneally
injected with 1 g kg-1 of glucose after 6 h of fasting. The blood glucose levels were monitored at the indicated intervals in the next 150 min. (D) Incremental area under the curve
(AUC) for the ipGTT data in (C). (E) Levels of IL-6 and IL-18 in mouse plasma. Data were presented as mean±SEM. * (p < 0.05) and ** (p < 0.01) compared with the control PBS
group (bar with white squares).

Figure 6. GC-VLNs reduced immune cell infiltration in eWAT of diet-induced obese mice. The mice described in Figure 5 were sacrificed after 15-week treatment.
eWAT was taken from each mouse and subjected to different analyses. (A) Weight percentage of eWAT/body weight. (B) Representative images of H&E-stained sections of
eWAT. Yellow arrows indicate CLSs in eWAT. (C) Representative images of eWAT SVF stained with an anti-F4/80-APC antibody. SVF was extracted from eWAT, stained with
the antibody which recognized macrophage surface marker F4/80, and subjected to flow cytometry analysis. To obtain enough cells, eWAT from 2 mice in each group were
combined to extract SVF. (D) Quantification of adipose tissue macrophages (ATMs) using the data obtained in (C). Data were presented as mean±SEM. * (p < 0.05) and ** (p <
0.01) compared with the control group (bar with white squares).
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Figure 7. GC-VLNs reduced inflammation in eWAT of diet-induced obese mice. The mice described in Figure 5 were sacrificed after 15-week treatment. One piece
of eWAT was ex vivo cultured, primed with LPS for 3 h, and stimulated with FFA sodium palmitate for 12 h. (A) Levels of IL-1β, IL-18, IL-6, and TNFα in the culture media. The
cytokine levels were normalized to the protein amount in each cultured eWAT. (B-C) Relative mRNA levels of inflammatory genes in eWAT, which were snap frozen during
sacrifice. (D) Immunoblot analysis of eWAT SVF. Each SVF sample was extracted from eWAT of 2 mice in each group. Data were presented as mean±SEM. * (p < 0.05) and **
(p < 0.01) compared with the control group (bar with white squares).

These eWATs were cultured ex vivo and
stimulated with LPS and FFA. The release of
cytokines, including IL-1β, IL-18, IL-6, and TNFα,
from eWAT in VLN-IV mice was decreased,
compared to control mice (Figure 7A). The cytokines
released from eWAT in VLN-OG mice tended to be
lower than in control mice but did not reach statistical
significance for most of them (Figure 7A). At the
molecular level, both orally and intravenously
administered GC-VLNs decreased transcription of the
Nlrp3, Pycard, Casp1, Il1b, Tnf, and Il6 genes in eWAT,
but had no effects on mRNA level of the Nek7 gene
(Figure 7B-C). At the protein level, the cleaved Casp1
and inflammasome components, including NLRP3,
Casp1, and ASC, were much lower in the SVF of
GC-VLN treated mice (Figure 7D). Altogether, it
seems that both IV- and OG-administered GC-VLNs
improved metabolic health and decreased NLRP3
inflammasome activity and inflammation in
diet-induced obese mice.

Lipids in GC-VLNs suppressed activation of
the NLRP3 inflammasome
Next, we tried to determine which category of
biomolecules in GC-VLNs was critical in mediating
the anti-NLRP3 inflammasome function. GC-VLNs
were first heat-treated to denature proteins in the
nanoparticles. Such heat-treated GC-VLNs retained

the ability to suppress the NLRP3 inflammasome in
LPS-primed BMDMs activated by ATP or FFA (Figure
8A and D), indicating that proteins in GC-VLNs were
not the key molecules mediating anti-inflammasome
function. Second, GC-VLNs were subjected to
sonication plus RNase treatment to deplete RNAs.
The integrity of these membrane-bound nanoparticles
was compromised with the sonication treatment and,
as a result, RNase could easily enter to degrade RNAs
[19]. Approximately 98% of RNAs in GC-VLNs were
removed by this treatment (Figure S9). The
RNA-depleted GC-VLNs still suppressed the NLRP3
inflammasome (Figure 8B and E), implying that the
majority of RNAs in GC-VLNs were not critical in
suppressing NLRP3 inflammasome activity. Since
neither proteins nor RNAs were critical in inhibiting
the NLRP3 inflammasome, it was likely that lipids in
GC-VLNs played a role in suppressing activation of
the NLRP3 inflammasome. To directly assess the role
of lipids in GC-VLNs, total lipids in GC-VLNs were
purified and re-assembled into liposomes, which
mimic the membrane-enclosed structure of GC-VLNs.
Such liposomes potently inhibited the NLRP3
inflammasome activated by ATP or FFA (Figure 8C
and F). Therefore, lipids in GC-VLNs are responsible
for suppressing activation of the NLRP3
inflammasome.
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Figure 8. Lipids from GC-VLNs suppressed NLRP3 inflammasome activation. (A and D) GC-VLNs were heated at 95 °C for 10 min to denature proteins. 9×1010
mL-1 of regular (reg) or heated GC-VLNs were preincubated with BMDMs for 16 h, followed by NLRP3 inflammasome activation using LPS+ATP (A) or LPS+FFA (D). (B and E)
GC-VLNs were added with 10 µg mL-1 of RNase, subjected to bath sonication at room temperature for 1.5 h, and incubated at 37 °C for an additional 1 h to degrade RNAs inside
the nanoparticles (S/R-treated). 9×1010 mL-1 of regular (reg) or RNA-depleted (S/R-treated) GC-VLNs were used. (C and F) Lipids were extracted from GC-VLNs and
reassembled into liposomes. 9×1010 mL-1 of regular (reg) GC-VLNs or liposomes from GC-VLN lipids were preincubated with BMDMs for 16 h, followed by NLRP3
inflammasome activation using LPS+ATP (C). In (F), different doses of liposomes from GC-VLN lipids were preincubated with cells for 16 h, followed by LPS and FFA treatment
to activate the NLRP3 inflammasome. Results were expressed as mean±SEM from three independent experiments. * (p < 0.05) and ** (p < 0.01) compared with LPS+ATP group
(black bar).

Specific phospholipid was identified to inhibit
NLRP3 inflammasome activity
During our studies, we noticed that GC-VLNs
from the local grocery shop did not consistently
suppress NLRP3 inflammasome activation. To ensure
consistency and freshness of raw material, garlic chive
seeds were purchased and plants were grown in a
greenhouse facility; plant leaves were freshly
harvested for VLN extraction. However, the
anti-inflammatory effects of GC-VLNs still varied –
sometimes they exerted strong anti-inflammasome
functions (active), but sometimes they lost such effects
(inactive) (Figure S10A-B). There was no significant
size difference between active and inactive GC-VLNs
(Figure S10C). The morphology and vesicularstructure of inactive GC-VLNs (Figure S10D) were
similar to those of active GC-VLNs (Figure 1B).
Generally, GC-VLNs obtained in the winter-spring
season, but not in summer-fall, had potent
anti-inflammasome function, although the underlying
mechanism was not clear. For all the studies
mentioned above, we always used active GC-VLNs.
Typically, one big batch of GC-VLNs was extracted
and tested for their anti-inflammasome function in
BMDMs. If we observed strong anti-inflammasome
function, the batch would be aliquoted, stored at -80
°C, and used for in vitro and in vivo studies.
Anti-inflammasome functions of GC-VLNs were

stable after -80 °C storage but still were subjected to
periodical cell culture tests to ensure their
bioactivities. The inactive GC-VLNs were usually
discarded and used only as negative controls in the
GC-VLN comparison analysis.
After lipids were identified as bioactive
molecules in GC-VLNs, total lipids were extracted
from active and inactive GC-VLNs and reassembled
into liposomes. Only liposomes prepared from active
GC-VLNs, but not from inactive GC-VLNs, showed
strong inhibitory effects on the downstream events of
NLRP3 inflammasome activation, including Casp1
autocleavage (Figure 9A), IL-1β release (Figure 9B),
and IL-18 release (Figure 9C). Liposomes from active
GC-VLNs also retained inhibitory effects on the
secretion of both IL-6 and TNFα, but liposomes from
inactive GC-VLNs lost such functions (Figure
S11A-B). The distinct anti-inflammatory properties of
lipids from active and inactive GC-VLNs provided
good sources that allowed us to compare their
composition and identify specific active biomolecules.
To compare the composition of lipids from active
and inactive GC-VLNs, total lipids from five
replicates of these two sources were extracted and
subjected to lipidomics analysis. The lipid profiles of
active and inactive GC-VLNs were very distinct
(Figure 9D and Table S2). Strikingly, the level of
phosphatidylcholine (PC) in active GC-VLNs was
much higher than the level in inactive GC-VLNs (43%
http://www.thno.org
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vs 26%). Figure 9E highlights eight PC species that
were most abundant in active GC-VLNs and whose
levels in active GC-VLNs were meanwhile at least
1.3-fold higher than levels in inactive GC-VLNs.
Among these PCs, PC(34:2) and PC(36:4) were most
abundant in active GC-VLNs, and the level of
PC(34:1) increased most significantly in active
GC-VLNs compared to inactive GC-VLNs. Therefore,
these three PC lipids were selected for further
evaluation. Isoform analysis revealed that in active
GC-VLNs, PC(34:2) was 1-palmitoyl-2-linoleoyl-snglycero-3-phosphocholine (PC(16:0/18:2)); PC(36:4)
was
dominantly
1,2-dilinoleoyl-sn-glycero-3phosphocholine (DLPC, PC(18:2/18:2)), with a tiny
amount
of
1-oleoyl-2-linolenoyl-sn-glycero-3phosphocholine; and PC(34:1) was 1-palmitoyl-2oleoyl-sn-glycero-3-phosphocholine (PC(16:0/18:1)).
To directly test their roles in NLRP3
inflammasome activation, PC(34:2), PC(34:1), and
DLPC (the dominant isoform of PC(36:4) in GCVLNs) were purchased and assembled into liposomes
to test their anti-inflammasome activity. Liposomes
prepared from the PC(36:4) isoform DLPC, but not
liposomes from control 1,2-dipalmitoyl-sn-glycero-3phosphocholine (PC (32:0)), PC(34:1), or PC(34:2),
potently inhibited Casp1 autocleavage (Figure 10A)
and IL-1β release (Figure 10B) upon NLRP3
inflammasome activation in BMDMs. SEM analysis
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showed that liposomes from PC(36:4) were
homogeneous individual nanoparticles (Figure S12A),
and NTA showed that these liposomes were
approximately 100 nm in diameter (Figure S12B).
DLPC-derived liposomes dose-dependently inhibited
Casp1 autocleavage (Figure 10C-D), IL-1β release
(Figure 10E and G), and IL-18 secretion (Figure 10F
and H) when the NLRP3 inflammasome was
activated by ATP or FFA in LPS-primed BMDMs.
DLPC-derived liposomes also inhibited secretion of
both IL-6 and TNFα (Figure S13A-D).

Discussion
In this study, we found that VLNs were present
in commonly consumed Allium vegetables. VLNs
from garlic chives, but not other Allium vegetables we
tested, potently suppressed NLRP3 inflammasome
activation in primary macrophages. Local injection of
GC-VLNs alleviated liver damage and reduced
inflammation in the mouse model of acute liver
injury. Long-term weekly administration of GC-VLNs
through oral gavage or intravenous injection
improved metabolic health and reduced chronic
inflammation in diet-induced obese mice. The
phospholipid DLPC was identified in GC-VLNs to
mediate anti-inflammasome functions.

Figure 9. Lipids from active and inactive GC-VLNs were subjected to lipidomic analysis. (A-C) BMDMs were preincubated with liposomes prepared from lipids of
active or inactive GC-VLNs, followed by NLRP3 inflammasome activation. (A) Immunoblot analysis of Casp1 p10 in cell lysates. (B) Levels of IL-1β in the culture media. (C) Levels
of IL-18 in the culture media. Results were expressed as mean±SEM from three independent experiments. * (p < 0.05) and ** (p < 0.01) compared with LPS+ATP group (black
bar). (D) Lipidome comparison of active and inactive GC-VLNs. PC: phosphatidylcholine; PE: phosphatidylethanolamine; PA: phosphatidic acid; PG: phosphatidylglycerol; MGDG:
monogalactosyldiacylglycerol; DGDG: digalactosyldiacylglycerol. (E) Abundance and fold change of top eight PC species in active GC-VLNs.
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Figure 10. DLPC was identified to suppress NLRP3 inflammasome activation. (A-B) BMDMs were preincubated with liposomes prepared from PC lipids for 16 h,
followed by LPS+ATP treatment to activate the NLRP3 inflammasome. (A) Immunoblot analysis of Casp1 p10 in cell lysates. (B) Levels of IL-1β in the culture media. (C-H)
BMDMs were preincubated with DLPC liposomes (PC(36:4)) for 16 h, followed by LPS+ATP or LPS+FFA treatment to activate the NLRP3 inflammasome. Cell lysates were
subjected to immunoblot analysis and cell-free media were used for cytokine measurement. Results were expressed as mean±SEM from three independent experiments. * (p <
0.05) and ** (p < 0.01) compared with LPS+ATP group or LPS+FFA group (black bar).

Garlic chive (A. tuberosum) is native to Shanxi
province located in north-central China and is
consumed by people in many Asian countries,
including China, Korea, Japan, and India [49]. This
Allium species has been reported to have anti-cancer,
anti-oxidant, and anti-inflammatory functions [49],
suggesting the medicinal potential of this plant. Over
40 compounds, including organosulfur compounds
and flavonoids often found in other Allium vegetables,
have been identified in garlic chive [50]. Among its
compounds, thiosulfinates were shown to induce
apoptosis of colon cancer cells and tuberoside M
suppressed proliferation of leukemia cells [51,52].
Studies on the anti-inflammatory function of garlic
chives are scarce. Here, we identified a new bioactive
agent in garlic chive – GC-VLN, membrane-enclosed
vesicle-like nanoparticles containing proteins, RNAs,
and lipids (Figure 1). Proteomics analysis of proteins
in GC-VLNs (Table S1) demonstrated the presence of
a series of plasma membrane proteins and
membrane-associated cytosolic proteins, indicating
the vesicle-like nature of GC-VLNs, based on the
guidelines from Minimal Information for Studies of
Extracellular Vesicles 2018 (MISEV2018) [53]. These
GC-VLNs potently inhibited NLRP3 inflammasomemediated inflammation in cell culture and animal
disease models (Figures 2, 3, 5-7). Therefore, our
research revealed that garlic chive’s newly identified
component GC-VLNs demonstrated a new bioactivity

– an anti-NLRP3 inflammasome function, which
significantly contributes to the basic understanding of
how garlic chive exerts its anti-inflammatory function.
Further investigation revealed that phospholipid
DLPC in GC-VLNs mediated the anti-NLRP3
inflammasome function (Figure 8-10). Lipids have
been found to either impede or activate the NLRP3
inflammasome. Omega-3 polyunsaturated fatty acids,
such as eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), inhibit activation of the
NLRP3 inflammasome [54], whereas saturated fatty
acids, such as palmitic acid, activate the NLRP3
inflammasome [14]. Oxidized PCs, including
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphoc
holine [55] and 1-O-alkyl-2-acetyl-sn-glycero-3phosphocholine (also called platelet-activating factor)
[56] activate the NLRP3 inflammasome. Our research
demonstrated
an
unprecedented
anti-NLRP3
inflammasome function of the phospholipid DLPC in
GC-VLNs. Phospholipid PCs have been regarded as
membrane bricks since they are the most abundant
phospholipids in plasma membranes and subcellular
organelles in eukaryotic cells [57]. Interestingly, some
PCs have been identified to serve directly as signaling
molecules. For example, 1-palmitoyl-2-oleoyl-snglycerol-3-phosphocholine has been identified as the
endogenous ligand for the nuclear receptor
peroxisome proliferator-activated receptor α (PPARα)
[58]. PPARδ in liver regulates the rhythmic level of
http://www.thno.org

Theranostics 2021, Vol. 11, Issue 19
1-stearoyl-2-oleoyl-sn-glycerol-3-phosphocholine in
serum, which modulates fatty acid use in muscle [59].
DLPC has been shown to decrease the release of TNFα
in the LPS-treated murine macrophage-like
RAW264.7 cell line [60], as well as in LPS-treated
Kupffer cells isolated from rats fed an
alcohol-containing diet [61]. A purified extract of
soybean lecithin (94-96% PC), which contains 40-52%
DLPC, protects baboons from alcohol-induced fibrosis
and cirrhosis [62]. Our research revealed another
interesting function of DLPC − it inhibits NLRP3
inflammasome activity.
Current NLRP3 inflammasome-related therapies
in clinical practice target its cleavage product, IL-1β,
using neutralizing IL-1β antibodies (Gevokizumab or
Canakinumab), IL-1 receptor antagonist (Anakinra),
or the soluble decoy IL-1 receptor (Rilonacept) [63].
Anakinra, Rilonacept, and Canakinumab have been
approved to treat cryopyrin-associated autoinflammatory syndrome patients [63], and Anakinra
has been found to reduce inflammation and plasma
glucose levels and enhance insulin secretion in
diabetic patients in clinical trials [64]. While cytokinetargeting therapies appear to be promising, they
target only IL-1β, not IL-18 or other downstream
events of the NLRP3 inflammasome. The treatments
are costly and sometimes cause adverse effects such as
redness, bruising, or pain at the injection site. Some
small-molecule chemicals, such as MCC950 [65] and
Bay 11-7082 [66], suppressed assembly and activation
of the NLRP3 inflammasome and reduced the severity
of NLRP3 inflammasome-driven disorders, such as
cryopyrin-associated autoinflammatory syndrome or
experimental autoimmune encephalomyelitis in mice.
Impeding assembly and activation of the NLRP3
inflammasome blocks all its downstream pathways
and theoretically offers greater therapeutic promise to
treat
NLRP3
inflammasome-driven
diseases.
However, the bioavailability, potency, and long-term
safety of these chemicals in humans have not been
well characterized.
GC-VLNs identified in this study potently
inhibited all the downstream pathways of the NLRP3
inflammasome through blockage of its assembly and
activation (Figure 2, S3, and S4). When administered
locally or systemically in mice, GC-VLNs effectively
suppressed acute or chronic inflammation in different
disease models (Figure 3, 5-7), suggesting the
promising efficacy of these dietary nanoparticles in
vivo. In the obesity study, three months of intravenous
or oral administration of GC-VLNs had no
detrimental effects on the general health of mice
(Figure 5). Orally given GC-VLNs can be absorbed
through the digestive tract and accumulated in kidney
and eWAT in obese mice. Intravenously administered
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GC-VLNs also significantly accumulated in kidney
and eWAT, implying the possibility of intrinsic tissue
selection of GC-VLNs after their absorption (Figure 4).
Dietary VLNs have been shown to have distinct
biodistribution in vivo. For example, grape VLNs
accumulated in intestinal stem cells [25], grapefruit
VLNs were detected in liver [24], and ginger VLNs
were found in the intestinal macrophages [67], liver,
and mesenteric lymph nodes [24] after oral gavage in
mice. The enrichment of PC in grapefruit VLNs was
critical in promoting the accumulation of these
nanoparticles in the liver [68]. Specific integrin
proteins of tumor-derived extracellular vesicles
enabled these vesicles to target specific tissues and
induced metastasis in these tissues [69]. The enriched
phosphatidylserine of tumor-derived extracellular
vesicles facilitates the recognition and uptake of these
vesicles by macrophages [70]. Therefore, the unique
biodistribution pattern of GC-VLNs reiterates the
notion that the lipid composition and/or specific
surface proteins of extracellular vesicles and dietary
VLNs may mediate their specific uptake by target
cells and tissues. Therefore, as a natural nano-carrier,
GC-VLN’s unique biodistribution, high efficacy, and
long-term safety in vivo demonstrated in our research
suggest their high therapeutic potential. In addition,
garlic chives generate abundant GC-VLNs (around
3.4×1011 g-1, Figure S1), can be easily cultivated at low
cost, and have been safely consumed as a daily
vegetable in many Asian countries for centuries
[26,49]. All these properties should facilitate their
translational application. Identification of DLPC as an
active anti-inflammasome component in GC-VLNs
would facilitate quality control of GC-VLNs, as well
as guide the grow-condition studies of garlic chive to
stabilize the anti-inflammatory function of GC-VLNs
in the future. However, as a pure lipid, DLPC alone
(nor its derived liposomes) lacks the specific lipid
composition and specific surface proteins of
GC-VLNs and therefore is not likely to share
GC-VLNs’ unique biodistribution in vivo. Further
studies on the bioavailability, efficacy, and safety of
DLPC in vivo are warranted.
Our previous studies have identified that VLNs
from ginger, shiitake mushroom, and honey inhibit
the NLRP3 inflammasome [19,20,27]. A microRNA
miR-4057 was identified in honey VLNs in inhibiting
NLRP3 inflammasome activation [20], but the active
components in ginger- and shiitake mushroomderived VLNs have not been elucidated. Our current
study identified VLNs from garlic chive – GC-VLNs –
with anti-inflammasome function and also revealed
that DLPC in GC-VLNs strongly suppresses the
NLRP3 inflammasome. Although GC-VLNs shared
the same anti-NLRP3 inflammasome as three VLNs in
http://www.thno.org
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our previous studies, this research has its own
importance and novelty as reasoned below:
1) In each of our studies, we screened 5-10 foods
from vegetables, fruits, spices, mushrooms, and
bee-related products. In our unpublished pilot
studies, we have screened more dietary VLNs. In total
we have tested VLNs from over 50 dietary sources. So
far we have found only four VLNs that inhibit the
NLRP3 inflammasome. Therefore, finding of
GC-VLNs with anti-inflammasome function, together
with our previous studies, establishes an implicit
consensus that anti-inflammasome function is unique
and possessed only by specific dietary VLNs. 2) This
study was designed to thoroughly assess the
therapeutic potential of GC-VLNs in combating acute
or chronic inflammation using acute liver failure and
obesity disease models. Our previous studies mainly
used cell culture or acute liver damage models to
provide proof-of-concept evidence for the antiinflammatory functions of dietary VLNs [19,20,27].
Other dietary VLN studies have not examined the role
of any dietary VLNs in obesity or acute liver failure
disease models. Therefore, our current study revealed
the possible new therapeutic application of dietary
VLNs in the prevention or treatment of chronic
inflammation in obesity. 3) This research identified
DLPC as an active component of GC-VLNs, compared
to microRNAs as the active components of honeyderived VLNs [20], indicating that GC-VLNs have a
completely new and different mechanism to inhibit
the NLRP3 inflammasome. Our two studies together
corroborate that nature develops diverse yet elegant
mechanisms to curb dysregulated inflammation in
humans. 4) This study highlights the important yet
underappreciated functions of lipids in dietary VLNs.
Many dietary ELN studies have demonstrated the
importance of microRNAs or other components in
dietary VLNs. For example, microRNAs in ginger
VLNs regulate the composition of the gut microbiota
and their functions [68]. Depletion of microRNAs in
milk VLNs led to altered expression of immunerelated genes and exacerbated intestinal inflammation
in Mdr1a-deficient mice [71]. Phytochemical shogaol
in ginger VLNs induced transcription of detoxifying/
antioxidant genes and protected mice from alcoholinduced liver damage [24]. The functions of lipids in
dietary VLNs are only beginning to be appreciated.
PA(34:2) from ginger-derived VLNs was reported to
specifically inhibit the growth of an oral pathogen,
Porphyromonas gingivalis, through interaction with the
outer membrane protein HBP35 of this pathogenic
bacterium and suppressing expression of some of its
virulence-related genes [72]. Our study uncovered
another lipid DLPC from GC-VLNs with antiinflammatory function. In the current study, we
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examined only the functions of DLPC in inhibiting the
NLRP3 inflammasome. It is possible that other lipid
species in GC-VLNs could contribute to the antiinflammasome functions of GC-VLNs, which will be
further investigated in the future.
In conclusion, GC-VLNs and their active
component DLPC with potent anti-inflammasome
activity represent a new type of bioactive agent with
potential to treat NLRP3 inflammasome-driven
diseases. In the future, it would be also important to
elucidate the precise molecular mechanism by which
GC-VLNs
and
DLPC
inhibit
the
NLRP3
inflammasome.

Materials and Methods
Macrophage culture
BMDMs from C57BL/6J mice were prepared as
described [73]. Bone marrow cells from mice were
grown in RPMI medium(Corning, Tewksbury, MA,
USA) containing 10% fetal bovine serum (FBS; Atlanta
Biologicals, Minneapolis, MN, USA, S1150), 20% L929
cell-conditioned medium, 50 μg mL-1 PenStrep
(Corning, Tewksbury, MA, USA), 2 mM glutamine
(Corning), 1 mM sodium pyruvate (Corning), and 10
mM HEPES buffer (Corning). To assess the regulatory
role of dietary VLNs in NLRP3 inflammasome
activation, BMDMs were preincubated with VLNs for
16 h, then incubated with 10 ng mL-1 LPS (InvivoGen,
San Diego, CA, USA, tlrl-peklps) for 3 h and 1000 µM
sodium palmitate for 12 h (Sigma, St. Louis, MO,
USA), or 2.5 mM ATP for 30 min (Sigma), or 5 μM
nigericin for 30 min (Enzo Life Sci, Farmingdale, NY,
USA), or 0.5% v/v alum for 5 h (ThermoFisher
Scientific, Waltham, MA, USA) to activate the NLRP3
inflammasome. To activate the AIM2 inflammasome,
BMDMs were incubated with LPS for 3 h, followed by
transfection with calf DNA (Sigma, D3664), 2 µg for
each well for 2 h. At the end of stimulation, the cells
were directly lysed in SDS loading buffer; cell culture
media were collected, centrifuged at 300 ×g for 5 min
to remove any cell debris, and subjected to cytokine
measurement or immunoblot analysis.

Mice
C57BL/6J and Nlrp3A350VneoR mice were
purchased from Jackson Laboratory (Bar Harbor, ME,
USA) and maintained in a specific pathogen-free
facility. Animal experiments were approved by the
Institutional Animal Care and Use Committee of
University of the Nebraska-Lincoln (Project ID 1421,
1973, and 1936). For the preparation of peritoneal
macrophages, 3% (v/v) brewer thioglycolate medium
(Sigma) was intraperitoneally injected into C57BL/6J
mice; 3 days later, peritoneal macrophages were
http://www.thno.org
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collected from the peritoneal fluid. To study the
biodistribution of GC-VLNs, GC-VLNs covalently
labeled with fluorescence dye in near infrared ranges
using ExoGlow-Vivo EV labeling kit (System
Biosciences, Palo Alto, CA, USA) and free dye control
from the same kit were orally or intravenously
administered to lean 8-week-old male C57BL/6J mice.
6 h later, the mice were sacrificed to harvest a variety
of tissues, which were assessed for fluorescence
signals using the Odyssey Clx imaging system
(LI-COR Biosciences, Lincoln, NE, USA). The same
labeled GC-VLNs were intravenously or orally given
to 21-week-old obese male C57BL/6J mice, which
were fed with a HFD (Bio-Serv, Flemington, NJ, USA,
F3282, 60% of fat calories) for 15 weeks. The mice were
sacrificed after 6 h to assess the fluorescence signals in
their tissues.
For the acute liver injury model, 8-week-old
male C57BL/6J mice were intraperitoneally
administered GC-VLNs at a dose of 1×1010 g-1. After
48 h, mice were intraperitoneally injected with 15 µg
kg-1 LPS (Sigma, L2630) and 500 mg kg-1 GalN (Sigma,
34539) to induce acute liver injury. After 6 h, animals
were sacrificed to collect serum and livers for further
analysis. The expression of the Nlrp3 gene is disrupted
in Nlrp3A350VneoR mice, which therefore serves a
Nlrp3-deficient mouse strain [7]. This mouse strain
was crossed with C57BL/6J mice to generate
heterozygous mice, which were used to generate wt
and Nlrp3-/- littermates. 8-week-old wt and Nlrp3-/female littermates were subjected to LPS/GalN
injection and sacrificed after 6 h.
For the diet-induced obesity study, 8-week-old
male C57BL/6J mice were fed with a HFD (Bio-Serv)
and randomly separated into three groups. When the
HFD feeding started, the mice in the control group
received PBS weekly through both IV and OG, the
mice in the VLN-IV group were given 1×1010 g-1
GC-VLNs through IV and PBS through OG, and the
mice in the VLN-OG group were administered 1×1010
g-1 GC-VLNs through OG and PBS through IV to
ensure all the mice were treated with the same
administration routes. Body weight of the mice was
measured weekly. After the 11-week treatment, the
mice were kept individually in a Phenomaster/
Labmaster caging system (TSE Systems, Chesterfield,
MO, USA) for 48 h. The first 24 h was the adaption
period, and the data from the last 24 h were used for
calculating food intake, water intake, and movement
counts. At the end of the 13-week treatment period,
the mice were subjected to an ipGTT. Briefly, the mice
were fasted for 6 h, followed by intraperitoneal
injection of 1g kg-1 glucose (Sigma). The levels of
blood glucose were measured every 30 min over a
period of 150 min using a Bayer Contour Next blood

9325
glucose monitoring system (Parsippany, NJ, USA).
After 15 weeks of treatment, the mice were sacrificed
to collect serum and eWAT for further analysis.

Garlic chive
The seeds of garlic chive (A. tuberosum) were
purchased from Richters Herbs (Goodwood, ON,
Canada) and grown in the greenhouse facility at the
University of Nebraska-Lincoln (Lincoln, NE, USA).
The temperature in the greenhouse facility was
controlled between 24 °C and 27 °C. Natural sunlight
was the main light source, supplemented with three
1000-watt high-pressure sodium lights turned on at 6
AM and off at 8 PM to ensure 14 h of light/day. The
plants were grown in a mixture of peat, soil, sand, and
vermiculite at the ratio of 5:3:2.5:2.5. The garlic chive
leaves were harvested bi-weekly to ensure that
maturation levels of leaves were comparable when
they were used to extract VLNs.

Isolation and characterization of VLNs
Bulbs of garlic and purple or white onion and
leaves of leek, scallion, and garlic chive were
purchased from local grocery shops, washed, and
minced. 2-5 g of minced materials were soaked in cold
PBS and shredded for 15 s in a kitchen blender. The
juice was filtered through a mesh sheet and
centrifuged at 500 ×g for 10 min, 2000 ×g for 20 min,
and 10,000 ×g for 30 min at 4 °C. The final supernatant
underwent ultracentrifugation at 100,000 ×g for 2 h at
4 °C using a SW-32TI rotor in an Optima XE-90
ultracentrifuge (Beckman Coulter, Brea, CA, USA).
The nanoparticle pellets were washed with cold PBS,
resuspended in PBS, and centrifuged at 10,000 ×g for
10 min at 4 °C to remove any aggregates. VLNs in PBS
were passed through a 200 nm Acrodisc filter (Pall
Laboratory, Port Washington, NY, USA) to sterilize
the solution. For TEM and SEM analysis, VLNs were
further purified using a sucrose gradient. Briefly, the
nanoparticles in PBS were loaded on sucrose
gradients of 8%, 30%, and 60% (w/v) and underwent
ultracentrifugation at 150,000 ×g for 16 h at 4 °C. The
fractions enriched with GC-VLNs were collected,
diluted in PBS, and subjected to ultracentrifugation at
100,000 ×g for 2 h at 4 °C. Characterization of VLNs,
including size and yield measurement, biomolecule
separation, and RNA depletion of GC-VLN, was
conducted as described [19,27]. For the detergent
treatment of VLNs, VLN solutions were added with
Triton X-100 (Sigma) at different concentrations,
vortexed for 30 s, kept at room temperature for 30
min, and subjected to particle number measurement
using a NanoSight NS300 instrument (Malvern,
Westborough, MA, USA).
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Labeling and uptake of GC-VLNs
The lipophilic dye DiI (2 µM) was gently mixed
with GC-VLNs in PBS for 30 min at 37 °C to label the
membrane lipids. 35-fold more PBS was added to the
mixture, and it was subjected to ultracentrifugation at
100,000 ×g for 2 h at 4 °C to remove free dye. The
obtained GC-VLNs were resuspended in PBS and
incubated at 37 °C for 1 h, ready to be incubated with
BMDMs. Proteins and RNAs inside GC-VLNs were
labeled with ExoGlow protein EV labeling kit and
ExoGlow RNA EV labeling kit (System Biosciences),
respectively, per manufacturer’s protocols. BMDMs
were incubated with the fluorescence-labeled
GC-VLNs for 16 h or the indicated time in the
time-course experiment, washed with PBS 4 times,
and fixed with 4% paraformaldehyde (Sigma). Images
were taken using an A1R-Ti2 confocal system (Nikon,
Melville, NY, USA).
For the distribution studies of GC-VLNs in mice,
fluorescence dye from ExoGlow-Vivo EV labeling kit
(EXOGV900A-1, System Biosciences) was used to
label GC-VLNs at the ratio of 60×1010 nanoparticles : 1
µl dye, per manufacturer’s protocol. The labeled
GC-VLNs were resuspended in 30 mL of PBS and
ultra-centrifuged at 100,000 ×g for 2 h at 4 °C to
remove the free dye. The wash step was repeated two
times. The obtained GC-VLNs covalently linked to the
dye were given to mice through oral gavage or
intravenous injection.

Electron microscopy
SEM analysis of active GC-VLNs and liposomes
was carried out for evaluation of particle shape and
size range [19,20]. GC-VLNs were fixed with 2.5%
glutaraldehyde and 1% tannic acid in 0.1 M
cacodylate buffer (pH7.2) for 1 h and collected using a
MF-Millipore membrane filter (50 nm pore size;
Millipore Sigma). The membrane was briefly dried,
mounted onto a SEM stub, further dried in the air for
2 h, and sputter-coated with a 2-3 nm thick layer of
chromium using a Desk V sputter (Denton Vacuum,
Moorestown, NJ, USA). SEM images of GC-VLNs
were obtained using a Hitachi S4700 Filed-Emission
SEM (Hitachi, Santa Clara, CA, USA).
Ultrastructure TEM was carried out for
conformational and vesicular analysis of active and
inactive GC-VLNs [20]. Pellets of GC-VLNs were
incubated with 2.5% glutaraldehyde in 0.1 M
cacodylate buffer (pH7.2) at room temperature for 1 h.
After two washes with the same buffer, the samples
were post-fixed with 1% osmium tetroxide in
deionized water at room temperature for 1 h to fix
lipids. Fixed VLNs were rinsed in deionized water
three times, followed by a dehydration process using
a graduated ethanol series, and embedded in Spurr

9326
medium mix (Electron Microscopic Sciences, Fort
Washington, PA, USA). A Leica UC7 ultramicrotome
(Allendale, NJ, USA) was used to cut the samples to
obtain ultrathin sections (~90 nm), which were
stained with uranyl acetate and lead citrate.
Ultrastructural images were collected using a Hitachi
H7500 TEM with a bottom-mount AMT digital
camera.

Lipid extraction, lipidomics analysis, and
liposome preparation
All lipid extraction reagents were highperformance liquid chromatography (HPLC) grade.
Chloroform (Sigma) was supplemented with 0.01%
butylated hydroxytoluene (Sigma) to protect
polyunsaturated lipids. 0.8 parts GC-VLNs in PBS
were added with 1 part chloroform and 2 parts
methanol in a glass tube, followed by vigorous
shaking. The mixture was added with 1 part
chloroform and 1 part water, vigorously shaken, and
centrifuged at 1000 ×g for 10 min. The lower layer
containing chloroform and lipids was collected in a
clean glass tube. The leftover solution was added with
1 part chloroform, mixed well, and centrifuged to
collect residue lipids. The chloroform extraction was
repeated one more time. All the chloroform layers
containing lipids were combined, washed once with
0.25 part of 1 M KCl solution, and once more with 0.25
part of water. The organic phase containing lipids was
dried at 60 °C, with a stream of nitrogen gas blowing
over the lipid solution. The dried lipids of five
replicates of inactive and active GC-VLNs were sent
to the Lipidomics Research Center at the Kansas State
University (Manhattan, KS, USA), where analysis was
conducted using a direct-infusion electrospray
ionization triple quadrupole 4000QTrap mass
spectrometer (Applied Biosystems, Foster City, CA,
USA) to determine the lipid composition or lipid
isoforms [74]. Lipid composition was presented as a
percentage of the total signal for the molecular
species, determined after normalizing the signals to
internal standards of the same lipid class.
To assemble lipids from GC-VLNs into
liposomes, 500 µl of distilled water were added to the
dried lipids, and the mixture was sonicated for 5 min
in a bath sonicator (Branson Ultrasonics, Danbury,
CT, USA) and further sonicated using a S-450D digital
sonifier unit (Branson Ultrasonics) in the mode of 10 s,
on and 20 s off for a total of 3 min. The phospholipids
PC(32:0), PC(34:1), PC(34:2), and DLPC were
purchased from Sigma, dissolved in chloroform,
aliquoted, and kept at -20 °C. To prepare liposomes
from these lipids, one aliquot was dried at 60 °C ,with
a stream of nitrogen gas blowing over the lipid
solution, and the dried lipids were suspended in 0.9%
http://www.thno.org
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saline or PBS. The mixture was vigorously vortexed
every 15 min for a total of 30 min and extruded
through a NanoSizer mini extruder using 100 nm
membrane (T&T Scientific, Knoxville, TN, USA)
following the manufacturer’s instructions.

Proteomics analysis of GC-VLNs
The pellets of purified GC-VLNs were lysed in
NuPAGE™ LDS sample buffer (ThermoFisher
Scientific, Waltham, MA, USA) and the lysate was run
in a Bolt™ 12% Bis-Tris Plus gel for 10 min, followed
by in-gel digestion with trypsin. The obtained
peptides were subjected to LC-MS/MS analysis using
a RSLCnano system (ThermoFisher Scientific)
coupled to a Q-Exactive HF mass spectrometer
(ThermoFisher Scientific). The resulting proteomics
data were analyzed with Mascot v 2.6.1 (Matrix
Science, Boston, MA, USA) using the common
contaminants
database
cRAP
(123
entries,
www.theGPM.org) and the Uniprot entries for
viridiplantae (retrieved on 04/30/2019, 7108828
entries). The identified peptides and proteins were
validated using Scaffold v4.8.9 (Proteome Software
Inc., Portland, OR). For peptides, if they reached
greater than 80.0% probability by the Peptide Prophet
algorithm [75] with Scaffold delta-mass correction,
their identifications were accepted. For proteins, if
they reached 99.0% probability by the ProteinProphet
algorithm [76] and contained at least 2 identified
peptides, their identifications were established.

ASC immunofluorescence staining and
oligomer analysis
ASC immunofluorescence staining was done as
described [19]. 1:200 anti-ASC rabbit antibody
(Adipogen, San Diego, CA, USA, AG25B0006C100)
and 1:200 Alexa Fluor-594-conjugated secondary
antibody (Invitrogen, Carlsbad, CA, USA, A-11037)
were used for ASC immunofluorescence staining. For
the ASC oligomer analysis, BMDMs were lysed 20
min with PBS containing 0.5% Triton X-100,
EDTA-free protease inhibitor cocktails (Roche,
Indianapolis, IN, USA) and centrifuged at 6,000 ×g at
4 °C for 15 min. The Triton-soluble supernatant was
collected
for
immunoblot
analysis.
The
Triton-insoluble pellets were rinsed with PBS twice,
resuspended in 300 µl PBS containing 2 mM of
disuccinimidyl suberate (ThermoFisher Scientific) to
crosslink the ASC oligomers at 37 °C for 30 min, and
centrifugated at 6,000 ×g at 4 °C for 15 min. The pellets
containing the crosslinked ASC oligomers were
resuspended in SDS loading buffer for immunoblot
analysis.
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Tissue H&E staining and liver injury marker
measurement
A small piece of liver or eWAT was soaked in
10% formalin solution (VWR, Radnor, PA, USA)
during mouse sacrifice. After overnight fixing, the
tissues were transferred to cold PBS and submitted to
the Veterinary Diagnostic Laboratory at the
University of Nebraska-Lincoln for further
processing. Briefly, the tissues were embedded in
paraffin, cut into 8 µm thick sections, and subjected to
routine H&E staining. The levels of liver injury
markers in serum, including AST and ALT, were
analyzed using a Vitros-250 Chemistry Analyzer
(Johnson & Johnson, New Brunswick, NJ, USA).

Tissue lysate preparation and immunoblot
analysis
Tissues were minced in lysis buffer (150 mM
NaCl, 50 mM Tris-HCl, pH7.5, 0.5% NP-40)
supplemented with protease inhibitor, homogenized
using a mini-homogenizer, and gently rotated for 30
min at 4 °C. The obtained tissue lysates were
centrifuged at 18,000 ×g at 4 °C for 20 min, and the
supernatant was collected and measured for protein
concentration. Tissue lysates that contained equal
amounts of proteins were loaded on the NuPAGE
Bis-Tris protein gel (Invitrogen) for immunoblot
analysis [19]. Primary antibodies used were
anti-NLRP3
mouse
antibody
(Adipogen,
AG20B0014C100, 1:1000); anti-ASC rabbit antibody
(Adipogen, AG25B0006C100, 1:1000); anti-Casp1
(p10) mouse antibody (Adipogen, AG20B0044C100,
1:1000); anti-tubulin rabbit polyantibody (Santa Cruz,
Dallas, TX, USA, SC-5286, 1:200); anti-Nek7 rabbit
antibody (Abcam, Cambridge, MA, USA, ab133514,
1:10000); and anti-IL-1β goat antibody (R&D systems,
Minneapolis, MN, USA, AF401NA, 1:2000).

Quantitative PCR (qPCR)
mRNAs were extracted using RNA-bee (TelTest, Friendswood, TX, USA) per the manufacturer’s
instructions. 1 µg of total RNA was used for reverse
transcription using a high-capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City,
CA, USA), followed by qPCR analysis using a CFX
Connect Real-time system (Bio-Rad, Hercules, CA,
USA). The genes of interest were normalized to the
Hprt gene.

Cytokine measurement and LDH release
Cytokine analysis and LDH release were
performed as described [19]. The release of LDH in
medium was assessed using a CytoTox 96
Nonradioactive Cytotoxicity Assay kit (Promega,
Madison, WI, USA). Cytokine level was measured
http://www.thno.org
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using ELISA kits, including IL-1β (eBioscience, San
Diego, CA, USA, 88701388), IL-18 (MBL, Woburn,
MA, USA, D042-3), TNFα (BioLegend, San Diego, CA,
USA, 430901), and IL-6 (BioLegend, 431301).

SVF preparation
Upon sacrifice, eWAT was soaked in Hank’s
balanced salt solution (HBSS, Sigma) on ice. After
being washed in cold HBSS two times, eWAT from 2
mice in the same group was combined and minced in
HBSS containing 1 mg mL-1 type I collagenase
(Sigma), followed by gently shaking at 37 °C for 30
min. Every 15 min, the tissue samples were further
mixed using a plastic pipette. After enzymatic
digestion, the samples went through a cell strainer to
remove any residue tissues. Cells were centrifuged at
300 ×g for 10 min to separate SVF pellets from floating
adipocytes.

Flow cytometry analysis
SVF cells or BMDMs were blocked with
TrueStain fcX (BioLegend) for 15 min on ice in PBS
containing 0.5% FBS, 2 mM EDTA. SVF cells were
incubated with F4/80-APC antibody (BioLegend) or
rat isotype-APC control antibody (BioLegend) for 30
min on ice. BMDMs were incubated with both
F4/80-APC antibody (BioLegend) and CD11-b-PE
antibody (BioLegend) for 30 min on ice. Both rat
isotype-APC and rat isotype-PE control antibodies
(BioLegend) were used in BMDMs as controls. The
cells were washed and subjected to flow cytometry
analysis using a DxP10 FACSort flow cytometer (BD
Biosciences, San Jose, CA, USA). The data were
analyzed with FlowJo (BD Biosciences).

Statistics
The results of cell culture experiments were
analyzed using Excel software. A two-tailed t test was
employed to compare differences between two
conditions. Each cell culture experiment was repeated
3 or 4 times. R version 3.6.0 (R Core Team, The R
Foundation for Statistical Computing, Vienna,
Austria) [77] was used to analyze the results of animal
experiments. The normality of the data was evaluated
using a Shapiro-Wilks test. Because a low p-value
from the Shapiro-Wilks test suggested that the data
were not normally distributed, they were evaluated
using a nonparametric Mann-Whitney test.
Otherwise, the data were assumed to be normally
distributed and analyzed using a two-tailed t test. For
all statistical analyses, p < 0.05 was indicated by * and
considered significant. p < 0.01 was indicated by **.
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